Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer - Ten year results of the Naples (GUN) study

Sabino De Placido, Ciro Gallo, Alfredo Marinelli, Francesco Perrone, Clorindo Pagliarulo, Giuseppe Petrella, Giovanni Delrio, Michela D'Istria, Lucia Del Mastro, Angelo Raffaele Bianco

Research output: Contribution to journalArticle

Abstract

Ten year disease-free survival (DFS) results of the Naples randomized trial of adjuvant tamoxifen (TM), 30 mg per day for 2 years versus no therapy according to receptor levels, are reported. From Feb. 1, 1978, through Dec. 31, 1983, 308 pre- and postmenopausal patients with early breast cancer entered the trial. Estrogen receptor (ER) data were available on 239 (77.6%) patients, progesterone receptor (PgR) data on 194 (63.0%), and both receptor data on 181 (58.8%). ER and PgR were assayed by dextran-coated charcoal technique in a single laboratory. The effect of adjuvant TM was significantly related to ER and PgR concentration of the primary tumor. The greatest TM benefit on DFS was evident in patients with the highest levels of receptors. The interaction between the treatment effect and receptor concentration was found whether ER and PgR were considered separately or together.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalBreast Cancer Research and Treatment
Volume16
Issue number2
DOIs
Publication statusPublished - Sep 1990

Keywords

  • adjuvant therapy
  • breast cancer
  • endocrine therapy
  • estrogen receptor
  • progesterone receptor
  • tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer - Ten year results of the Naples (GUN) study'. Together they form a unique fingerprint.

  • Cite this